Neutralizing antibodies against sars-cov-2

The antibody or antigen-binding fragment thereof of any of the preceding claims, which binds to receptor binding domain (RBD) of spike protein of SARS-CoV-2.

The antibody or antigen-binding fragment thereof of any of the preceding claims, further comprising one or more amino acid residue mutations yet retaining specific binding to RBD of spike protein of SARS-CoV-2.

The antibody or antigen-binding fragment thereof of any of the preceding claims, wherein at least one of the mutations is in one or more of the CDR sequences, and/or in one or more of the VH or VL sequences but not in any of the CDR sequences.

The antibody or antigen-binding fragment thereof of any of the preceding claims, further comprising an immunoglobulin constant region, optionally a constant region of human Ig, or optionally a constant region of human IgG.

The antibody or antigen-binding fragment thereof of any of the preceding claims, wherein the constant region comprises a constant region of human IgG1 or IgG4.

The antibody or antigen-binding fragment thereof of claim 9, wherein the heavy chain constant region of human IgG1 comprises SEQ ID NO:

• 12, or a sequence having at least 80% sequence identity thereof;
• or wherein the heavy chain constant region of human IgG4 comprises SEQ ID NO:
• 13, or a sequence having at least 80% sequence identity thereof.

The antibody or an antigen-binding fragment thereof of any of the preceding claims, which is fully human antibody, chimeric antibody, monoclonal antibody, a bispecific antibody, a multi-specific antibody, recombinant antibody, labeled antibody, bivalent antibody, anti-idiotypic antibody or a fusion protein.

The antibody or antigen-binding fragment thereof of any of the preceding claims, which is a diabody, a Fab, a Fab′, a F(ab′)2, a Fd, an Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)2, a bispecific dsFv (dsFv-dsFv′), a disulfide stabilized diabody (ds diabody), a single-chain antibody molecule (scFv), an scFv dimer (bivalent diabody), a multispecific antibody, a camelized single domain antibody, a nanobody, a domain antibody, or a bivalent domain antibody.

The antibody or antigen-binding fragment thereof of any of the preceding claims, which is bispecific.

The antibody or antigen-binding fragment thereof of any of the preceding claims linked to one or more conjugate moieties.

A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of any of the preceding claims, and a pharmaceutically acceptable carrier.